Stock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates

Stock Track

2025/11/10

Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.

The company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.

Despite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing "evolving competitive dynamics." This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1154082935"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154082935\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154082935?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154082935","market":"hk","top_or_hot":-1,"title":"Stock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates","media":"Stock Track","content":"<p>Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.</p>\n\n<p>The company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.</p>\n\n<p>Despite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing \"evolving competitive dynamics.\" This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Roivant Sciences Plunges 6.11% in Pre-market Following Q2 Earnings Miss and Mixed Pipeline Updates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-11-10 22:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.</p>\n\n<p>The company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.</p>\n\n<p>Despite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing \"evolving competitive dynamics.\" This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1154082935","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154082935","pubTimestamp":1762784905,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"股票追踪|Roivant Sciences在第二季度盈利未达预期和混合管道更新后盘前暴跌6.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings that fell short of analyst expectations, coupled with mixed updates on its drug pipeline.\nThe company posted a quarterly revenue of $1.571 million, significantly below the FactSet estimate of $5.6 million. Roivant's net loss for the quarter was $166.039 million, or $0.17 per share, which was better than the expected loss of $0.33 per share. However, the income from operations came in at -$306.233 million, missing the IBES estimate of -$277.8 million.\nDespite the earnings miss, Roivant highlighted positive developments in its drug pipeline. The company reported favorable results from its Phase 3 VALOR study of brepocitinib in dermatomyositis, with plans to file a New Drug Application (NDA) in the first half of 2026. Additionally, Roivant's subsidiary Immunovant shared promising data on its treatment for Graves' disease. However, the company announced a delay in reporting results from its thyroid eye disease studies, now expected in the first half of 2026, citing \"evolving competitive dynamics.\" This mixed bag of clinical updates, combined with the financial underperformance, appears to have unsettled investors, leading to the pre-market decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}